Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
HGH Fragment 176-191
In plain language
Fragment 176-191 (synonym of AOD-9604) — C-terminal fragment focused entirely on fat metabolism.
For researchers
Fragment 176-191 is the amino acid stretch 176-191 from the C-terminus of human growth hormone — a synonymous name for the molecule AOD-9604, developed at Monash University (Melbourne) by Frank Ng's group. Its marketing designation varies between the two names depending on manufacturer, but chemically it refers to the same modified nonapeptide fragment. Structurally the molecule retains the lipolytic activity of full but lacks the hyperglycemic and mitogenic profile. The mechanism includes activation of β3-adrenergic receptors in adipocytes, followed by hormone-sensitive lipase (HSL) and β-oxidation in mitochondria. In Phase IIb Metabolic Pharmaceuticals clinical trials (2007), significant reduction of body fat mass is described without changes in lean mass, insulin sensitivity or serum . In modern research protocols, standard dose is 250-500 mcg s.c. fasted for maximum lipolysis. Half-life ~30 minutes. Often combined with / stacks, where the fragment covers the pure lipolytic component without adding -dependent mitogenic signals. Storage: -20°C lyophilized; reconstituted solution stable 21 days at 2-8°C.
Scientific literature
Other peptides
Information about HGH Fragment 176-191 is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.
